Abstract: Lighting system including mounting post, mounting body, first lighting module, and second lighting module. Mounting post has first end spaced apart along longitudinal axis from second end. Mounting body has first end being spaced apart along another longitudinal axis from second end. First end of mounting body is pivotally connected at first pivot axis by first pivot joint with first end of mounting post. First lighting module includes first semiconductor light-emitting device in first housing and is pivotally connected at first pivot axis by first pivot joint with first end of mounting body and with first end of mounting post. Second lighting module includes second semiconductor light-emitting device in second housing and is pivotally connected at second pivot axis by second pivot joint with second end of mounting body.

Abstract: A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Abstract: Lighting system including first and second enclosures, and pivotable joint assembly. First enclosure is elongated along first longitudinal axis and configured for mounting array of plurality of lighting modules; and includes: two opposing end panels spaced apart along first axis; first and second spaced-apart pairs of opposing elongated side panels; and four elongated enclosure edges joining together first and second pairs of side panels. Second enclosure is elongated along second longitudinal axis and configured for containing lighting module power supply; and includes: two opposing end panels spaced apart along second axis; third and fourth spaced-apart pairs of opposing elongated side panels; and four elongated enclosure edges joining together third and fourth pairs of side panels.

Abstract: Lighting system including mounting post, mounting body, first lighting module, and second lighting module. Mounting post has first end spaced apart along longitudinal axis from second end. Mounting body has first end being spaced apart along another longitudinal axis from second end. First end of mounting body is pivotally connected at first pivot axis by first pivot joint with first end of mounting post. First lighting module includes first semiconductor light-emitting device in first housing and is pivotally connected at first pivot axis by first pivot joint with first end of mounting body and with first end of mounting post. Second lighting module includes second semiconductor light-emitting device in second housing and is pivotally connected at second pivot axis by second pivot joint with second end of mounting body.

Abstract: Lighting system including: lighting module having semiconductor light-emitting device; first lens module; and asymmetric second lens module. Second lens module includes diverging lens configured for causing divergence of converged light emissions away from lens axis. Second lens module includes: lens body having light output surface spaced apart along light transmission axis from light input surface, lens body having longitudinal axis and lateral axis, the longitudinal and lateral axes being transverse to light transmission axis; light output surface having asymmetric curvilinear contour formed by convex region overlapping in directions along lateral axis with concave region, the asymmetric curvilinear contour uniformly extending in directions along the longitudinal axis.

Abstract: Lighting system including: lighting module having semiconductor light-emitting device; first lens module; and second lens module. First lens module may include: converging lens; or diverging lens having light output surface including raised region shaped as sliced torus; or diverging lens having light output surface including contoured lens screen having lenticular or microprismatic features. Converging lens may have total internal reflection side surface with frusto-conical shape. Second lens module may include diverging lens having light output surface spaced apart from light input surface that may include lens screen having lenticular or microprismatic features. Lighting system may include additional lighting modules and may include further lens modules that may be detachable and interchangeable.

Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.

Abstract: Lighting system including: lighting module having semiconductor light-emitting device; first lens module; and second lens module. First lens module may include: converging lens; or diverging lens having light output surface including raised region shaped as sliced torus; or diverging lens having light output surface including contoured lens screen having lenticular or microprismatic features. Converging lens may have total internal reflection side surface with frusto-conical shape. Second lens module may include diverging lens having light output surface spaced apart from light input surface that may include lens screen having lenticular or microprismatic features. Lighting system may include additional lighting modules and may include further lens modules that may be detachable and interchangeable.

Abstract: Lighting system including first and second enclosures, and pivotable joint assembly. First enclosure is elongated along first longitudinal axis and configured for mounting array of plurality of lighting modules; and includes: two opposing end panels spaced apart along first axis; first and second spaced-apart pairs of opposing elongated side panels; and four elongated enclosure edges joining together first and second pairs of side panels. Second enclosure is elongated along second longitudinal axis and configured for containing lighting module power supply; and includes: two opposing end panels spaced apart along second axis; third and fourth spaced-apart pairs of opposing elongated side panels; and four elongated enclosure edges joining together third and fourth pairs of side panels.

Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.

Abstract: A method of manufacture of an anhydrous cosmetic composition comprising the mixing of dried calcium chloride with liquid carrier material and fragrance comprising a solvent to give a give a base composition, followed by the gassing of the base composition with a propellant to give an aerosol composition, wherein the fragrance and the solvent therein are pre-mixed and this mixture comprises one or more components having a log P of greater than 5.5 and a vapour pressure at 25° C. of less than 0.001 mm Hg (0.1333 Pa) and does not comprise dipropyleneglycol at 3% or greater of this mixture; the method enhancing the homogeneity and stability of the composition.

Abstract: A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Abstract: We provide an alkylation process, comprising: separating and recycling a hydrogen gas and a hydrogen chloride from an offgas of a hydrogenation reactor; wherein the hydrogen gas is recycled to the hydrogenation reactor; and wherein the hydrogen chloride is recycled to an alkylation reactor. We also provide an alkylation process unit for performing this process.